Hbot denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for hbot are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Hyperbaric Oxygen Therapy on Not-FDA-Approved Grounds

Hyperbaric oxygen therapy has FDA clearance for a defined set of indications — the FDA classifies HBOT chambers as medical devices and has recognized specific clinical uses. However, UHC may issue a "not-FDA-approved" denial when (a) the diagnosis listed on the claim does not match one of the FDA-recognized indications, or (b) the specific HBOT protocol or device being used has not received the applicable FDA clearance. This denial category is distinct from "experimental" but the two often overlap in practice.

## Why This Denial Is Appealable

If the patient's diagnosis falls within an FDA-recognized indication for HBOT, this denial is based on an incorrect or incomplete characterization of the FDA's position — and that is directly challengeable. The FDA's list of cleared indications is publicly available and should be referenced explicitly in the appeal. Under ACA §2719, non-grandfathered plans must provide internal appeal rights and IRO access. Under ERISA §503, employer plans must afford a full-and-fair review. The external-review deadline is approximately four months from the denial; check your EOB for the exact date. Expedited review is available for urgent clinical situations.

## The Appeal Process

1. Obtain the FDA's current 510(k) clearance or approval documentation for the HBOT device being used and confirm the indication matches the patient's diagnosis. 2. File a Level 1 internal appeal with UHC, citing the FDA document by its public identifier and attaching a copy. 3. Include a prescriber letter confirming the treatment is being delivered within the FDA-cleared indication for this patient's specific diagnosis. 4. If the internal appeal is denied, request external review through UHC's IRO; the independent reviewer applies the applicable clinical standard, not just UHC's internal policy.

## Documentation to Gather

• FDA clearance documentation: The publicly available FDA record confirming HBOT clearance for the applicable indication — downloadable from the FDA's 510(k) database.
• Diagnosis confirmation: Chart notes, imaging, lab reports, or surgical records confirming the diagnosis code matches an FDA-recognized HBOT indication.
• Prescribing label / device labeling: The device manufacturer's FDA-approved labeling listing cleared indications.
• Professional-society support: A statement from the applicable guideline organization (e.g., the Undersea and Hyperbaric Medical Society) confirming the indication is within accepted clinical practice.
• Medical-necessity letter: Physician letter explicitly connecting the patient's diagnosis to the FDA-cleared indication and the UHC policy criterion.

## Criteria-Mapping Structure

Build a table that directly confronts the denial rationale:

| UHC Denial Basis | Patient-Specific Rebuttal | |---|---| | [Quote UHC's "not-FDA-approved" rationale verbatim] | [Cite FDA document reference, page/section, and the exact indication language matching this patient's diagnosis] |

Attach the FDA clearance record as Exhibit A and the prescribing/device labeling as Exhibit B. This structure leaves no room for the reviewer to sustain the denial on a technicality.